Serina Therapeutics stock analysis
Want to see SER full AI Analyst Report?
Serina Therapeutics (SER) Stock Price & Analysis
SER Stock Chart & Stats
- Day’s Range
- $1.35 - $1.46
- 52-Week Range
- $1.14 - $4.26
- Previous Close
- $1.37
- Volume
- N/A
- Average Volume (3M)
- 61.95K
- Market Cap
- $35.87M
- Enterprise Value
- $34.79M
- Total Cash (Recent Filing)
- $19.40M
- Total Debt (Recent Filing)
- $3.37M
- Price to Earnings (P/E)
- ―
- Beta
- 0.86
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- -0.27
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Drug-delivery Platform
Serina’s POZ platform targets meaningful therapeutic improvements by extending drug action and potentially enhancing tolerability and efficacy. A reusable delivery technology can support multiple candidates and create strategic value beyond any single development program if clinical validation is achieved.
Low Leverage And Positive Equity
Very low debt reduces fixed financial obligations and preserves flexibility while the company funds research and development. Positive equity and a larger asset base than in prior annual reports provide a stronger capital foundation, although operating losses still require careful financing management.
Simplified Capital Structure
Eliminating the former preferred designation removes an outstanding security class and clarifies the current equity structure. This can simplify future corporate actions, make shareholder rights easier to understand, and provide greater flexibility when considering future financing instruments.
Bears Say
Minimal Commercial Revenue
The company has not yet demonstrated meaningful commercial revenue relative to its operating cost base. Large losses indicate that current activities remain dependent on development success, partnerships, or external capital rather than an established revenue engine with proven operating leverage.
Persistent Cash Burn
Deeply negative operating and free cash flow show that the business is consuming substantial cash to fund operations and development. Continued burn limits internal funding capacity and makes future progress dependent on securing additional capital before resources become constrained.
Equity Financing And Dilution Risk
The financing agreement improves access to working capital but relies on issuing new common shares, which can dilute existing holders as capital is raised. Dependence on equity funding also signals that ongoing operations and development may not yet be supported by internally generated cash.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
What is Serina Therapeutics’s market cap?
When is Serina Therapeutics’s upcoming earnings report date?
How were Serina Therapeutics’s earnings last quarter?
Is Serina Therapeutics overvalued?
Does Serina Therapeutics pay dividends?
What is Serina Therapeutics’s EPS estimate?
How many shares outstanding does Serina Therapeutics have?
What happened to Serina Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Serina Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Serina Therapeutics Stock Smart Score
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven A. Ledger
- Employees
- 16
- Website
- www.serinatx.com
- Address
- 601 Genome Way, Huntsville, AL, 35806, US
Serina Therapeutics (SER) Earnings & Revenues
SER Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |











